{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:33:05Z","timestamp":1758807185218,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["82\/14\/2012\/PHGEN(TF)\/ BMS"],"award-info":[{"award-number":["82\/14\/2012\/PHGEN(TF)\/ BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00228-022-03345-8","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:03:21Z","timestamp":1654167801000},"page":"1321-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia"],"prefix":"10.1007","volume":"78","author":[{"given":"Bharati","family":"Shriyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parsshava","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharath","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apeksha S.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravina","family":"Govalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjunath Nookala","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-6667","authenticated-orcid":false,"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"3345_CR1","doi-asserted-by":"publisher","unstructured":"Hu Y, Li Q, Hou M et al (2021) Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease Study 2019. JCO Glob Oncol 1429\u20131441. https:\/\/doi.org\/10.1200\/GO.21.00194","DOI":"10.1200\/GO.21.00194"},{"key":"3345_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. JCO 22:935\u2013942. https:\/\/doi.org\/10.1200\/JCO.2004.03.050","journal-title":"JCO"},{"key":"3345_CR3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037. https:\/\/doi.org\/10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"key":"3345_CR4","doi-asserted-by":"publisher","unstructured":"Bhutani N (2020) Chronic myeloid leukemia in India: a review. https:\/\/doi.org\/10.5281\/ZENODO.3926873","DOI":"10.5281\/ZENODO.3926873"},{"key":"3345_CR5","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/jcph.953","volume":"57","author":"BA Adeagbo","year":"2017","unstructured":"Adeagbo BA, Olugbade TA, Durosinmi MA et al (2017) Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance. J Clin Pharmacol 57:1554\u20131563. https:\/\/doi.org\/10.1002\/jcph.953","journal-title":"J Clin Pharmacol"},{"key":"3345_CR6","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028. https:\/\/doi.org\/10.1182\/blood-2007-10-116475","journal-title":"Blood"},{"key":"3345_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pgs-2016-0103","volume":"18","author":"Z-P Jiang","year":"2017","unstructured":"Jiang Z-P, Zhao X-L, Takahashi N et al (2017) Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 18:35\u201356. https:\/\/doi.org\/10.2217\/pgs-2016-0103","journal-title":"Pharmacogenomics"},{"key":"3345_CR8","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499. https:\/\/doi.org\/10.1182\/blood-2006-07-036012","journal-title":"Blood"},{"key":"3345_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","volume":"82","author":"H Gurney","year":"2007","unstructured":"Gurney H, Wong M, Balleine RL et al (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82:33\u201340. https:\/\/doi.org\/10.1038\/sj.clpt.6100201","journal-title":"Clin Pharmacol Ther"},{"key":"3345_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/hdy.2016.20","volume":"116","author":"J Graffelman","year":"2016","unstructured":"Graffelman J, Weir BS (2016) Testing for Hardy-Weinberg equilibrium at biallelic genetic markers on the X chromosome. Heredity 116:558\u2013568. https:\/\/doi.org\/10.1038\/hdy.2016.20","journal-title":"Heredity"},{"key":"3345_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185\u2013202. https:\/\/doi.org\/10.1007\/s10928-007-9081-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3345_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s13318-015-0292-3","volume":"41","author":"A-A Golabchifar","year":"2016","unstructured":"Golabchifar A-A, Rezaee S, Dinan NM et al (2016) Population pharmacokinetic analysis of the oral absorption process and explaining intra-subject variability in plasma exposures of imatinib in healthy volunteers. Eur J Drug Metab Pharmacokinet 41:527\u2013539. https:\/\/doi.org\/10.1007\/s13318-015-0292-3","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3345_CR13","doi-asserted-by":"publisher","unstructured":"Park G, Park WS, Bae S et al (2016) Population pharmacokinetics of imatinib mesylate in healthy Korean subjects. Transl Clin Pharmacol 24:96. https:\/\/doi.org\/10.12793\/tcp.2016.24.2.96","DOI":"10.12793\/tcp.2016.24.2.96"},{"key":"3345_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 Update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"3345_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M et al (2019) Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update. Clin Pharmacol Ther 105:1095\u20131105. https:\/\/doi.org\/10.1002\/cpt.1304","journal-title":"Clin Pharmacol Ther"},{"key":"3345_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595219","volume":"11","author":"H Abdullah-Koolmees","year":"2021","unstructured":"Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM (2021) Pharmacogenetics Guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines. Front Pharmacol 11:595219. https:\/\/doi.org\/10.3389\/fphar.2020.595219","journal-title":"Front Pharmacol"},{"key":"3345_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.569843","volume":"11","author":"Y Chen","year":"2020","unstructured":"Chen Y, Dong X, Wang Q et al (2020) Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia. Front Pharmacol 11:569843. https:\/\/doi.org\/10.3389\/fphar.2020.569843","journal-title":"Front Pharmacol"},{"key":"3345_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","volume":"35","author":"V Gotta","year":"2013","unstructured":"Gotta V, Buclin T, Csajka C, Widmer N (2013) Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Ther Drug Monit 35:150\u2013167. https:\/\/doi.org\/10.1097\/FTD.0b013e318284ef11","journal-title":"Ther Drug Monit"},{"key":"3345_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/pgs-2018-0139","volume":"20","author":"Q Wang","year":"2019","unstructured":"Wang Q, Jiang Z-P, Yu E-Q et al (2019) Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. Pharmacogenomics 20:251\u2013260. https:\/\/doi.org\/10.2217\/pgs-2018-0139","journal-title":"Pharmacogenomics"},{"key":"3345_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A Di Paolo","year":"2014","unstructured":"Di Paolo A, Polillo M, Capecchi M et al (2014) The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14:328\u2013335. https:\/\/doi.org\/10.1038\/tpj.2014.7","journal-title":"Pharmacogenomics J"},{"key":"3345_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","volume":"63","author":"D Menon-Andersen","year":"2009","unstructured":"Menon-Andersen D, Mondick JT, Jayaraman B et al (2009) Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 63:229\u2013238. https:\/\/doi.org\/10.1007\/s00280-008-0730-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"3345_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","volume":"60","author":"H Schmidli","year":"2005","unstructured":"Schmidli H, Peng B, Riviere G-J et al (2005) Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 60:35\u201344. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02372.x","journal-title":"Br J Clin Pharmacol"},{"key":"3345_CR23","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G et al (2019) Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther 41:2558-2570.e7. https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.009","journal-title":"Clin Ther"},{"key":"3345_CR24","unstructured":"021588s024lbl.pdf"},{"key":"3345_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/PGPM.S105208","volume":"10","author":"R Ankathil","year":"2017","unstructured":"Ankathil R (2017) ABCB1 genetic variants in leukemias: current insights into treatment outcomes. PGPM 10:169\u2013181. https:\/\/doi.org\/10.2147\/PGPM.S105208","journal-title":"PGPM"},{"key":"3345_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/PGPM.S86672","volume":"9","author":"S Tulsyan","year":"2016","unstructured":"Tulsyan S, Mittal RD, Mittal B (2016) The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmgenomics Pers Med 9:47\u201358. https:\/\/doi.org\/10.2147\/PGPM.S86672","journal-title":"Pharmgenomics Pers Med"},{"key":"3345_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","volume":"28","author":"L-N Ni","year":"2011","unstructured":"Ni L-N, Li J-Y, Miao K-R et al (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265\u2013269. https:\/\/doi.org\/10.1007\/s12032-010-9456-9","journal-title":"Med Oncol"},{"key":"3345_CR28","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.1038\/s41598-020-69326-y","volume":"10","author":"C-H Hsin","year":"2020","unstructured":"Hsin C-H, Stoffel MS, Gazzaz M et al (2020) Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Sci Rep 10:12457. https:\/\/doi.org\/10.1038\/s41598-020-69326-y","journal-title":"Sci Rep"},{"key":"3345_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2125.2005.02229.x","volume":"59","author":"A Owen","year":"2005","unstructured":"Owen A, Goldring C, Morgan P et al (2005) Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 59:365\u2013370. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02229.x","journal-title":"Br J Clin Pharmacol"},{"key":"3345_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/dna.2009.0953","volume":"29","author":"G G\u00fcm\u00fc\u015f-Akay","year":"2010","unstructured":"G\u00fcm\u00fc\u015f-Akay G, R\u00fcstemo\u011flu A, Karada\u011f A, Sunguro\u011flu A (2010) Haplotype-based analysis of MDR1\/ABCB1 gene polymorphisms in a Turkish population. DNA Cell Biol 29:83\u201390. https:\/\/doi.org\/10.1089\/dna.2009.0953","journal-title":"DNA Cell Biol"},{"key":"3345_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","volume":"55","author":"I Judson","year":"2005","unstructured":"Judson I, Ma P, Peng B et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379\u2013386. https:\/\/doi.org\/10.1007\/s00280-004-0876-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"3345_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/bcp.15122","volume":"88","author":"\u00c1 Corral Alaejos","year":"2022","unstructured":"Corral Alaejos \u00c1, Zarzuelo Casta\u00f1eda A, Jim\u00e9nez Cabrera S et al (2022) External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol 88:1913\u20131924. https:\/\/doi.org\/10.1111\/bcp.15122","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03345-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03345-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03345-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:06:57Z","timestamp":1657782417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03345-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3345"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03345-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (TMC-ACTREC IEC-III, Registration number: ECR\/149\/Inst\/MH\/2013) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}